

Date: 10.02.2018

To,
The Secretary,
The B.S.E Limited
Floor 25, P.J. Towers,
Dalal Street,
Mumbai - 400 001

Sub: Submission of Un-Audited Standalone Financials Results of the Company and Limited Review Report as per Provisions of Regulation 33 of SEBI (LODR) Regulations, 2015.

Please find enclosed here with the following Documents in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015:

1. Financial Results: Un-Audited Standalone Financial Results of the company for the Third Quarter Ended 31st December, 2017.
2. Limited Review Report: A Certified Copy of the Limited Review Report on Standalone Financials for the Third Quarter Ended 31st December, 2017 by the Auditors.

This is for your Information and Necessary Records.

Thanking you
For **TRIMURTHI LIMITED**



Arun Kumar Bhangadia
Managing Director
DIN: 00021024



TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

Date: 10.02.2018

To,
The Secretary,
The B.S.E Limited
Floor 25, P.J. Towers,
Dalal Street,
Mumbai- 400 001

Sub: Outcome of the Board Meeting held on 10/02/2018 as per Regulation 30, 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

The Board of Directors of the Company at its meeting held today, Saturday, the 10th day of February, 2018 at Registered Office, have approved and taken on record the following:

1. The Board has considered and approved the minutes of the previous board meeting.
2. The Board has considered and approved the Unaudited Standalone Financial Results for the Quarter III ended 31st December, 2017 along with Limited Review Report issued by the Statutory Auditors of the Company in compliance with Indian Accounting Standards (Ind-AS), SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013.

There being no other matter meeting of the Board of Directors concluded with the vote of thanks.

The Meeting of the Board of Directors of the company commenced at 01.30 P.M. and Concluded at 02:30 PM

Request you to take same on records.

Thanking you
for TRIMURTHI LIMITED



Arun Kumar Bhangadia
Managing Director
DIN: 00021024



TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

TRIMURTHI LIMITED

(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)

SCHEDULE III OF THE COMPANIES ACT 2013

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER III AND 9 MONTHS ENDED 31ST DECEMBER, 2017




TRIMURTHI
GROUP — (Rs. In Lakhs)

PART-I

Particulars	Quarter Ended			Nine Months Ended	
	31-12-2017	30/09/2017	31-12-2016	31-12-2017	31-12-2016
	Unaudited	UnAudited	Unaudited	Unaudited	Unaudited
I. Income From Operations					
Net Sales / Income from Operations	104.54	27.25	79.73	182.67	277.26
Other Income	0.06	0.05	31.81	2.22	58.17
II. Total Income	104.60	27.30	111.54	184.89	335.43
III. Expenses					
a. Consumption of Raw Material	-Nil-	-Nil-	Nil	-Nil-	-Nil-
b. Purchase of Traded Goods/Shares	111.17	2.79	69.93	114.25	306.68
c. (Increase)/Decrease in stock in trade and work in Progress	(29.36)	(0.53)	6.98	(7.97)	(34.31)
d. Employee benefits expense	7.52	5.47	5.11	18.80	15.83
e. Rent	0.95	0.55	0.35	2.25	1.95
f. Finance Cost	0.00	0.00	0.00	0.00	0.00
g. Depreciation	4.26	4.01	3.46	11.96	8.75
h. Other Expenditure	3.41	2.74	2.47	11.51	15.52
Total	97.95	15.03	88.31	150.80	314.33
IV. Profit/ (Loss) before Exceptional and Tax (III-IV)	6.65	12.27	23.23	34.09	21.10
V. Exceptional Items	Nil	Nil	Nil	Nil	Nil
VI. Profit/ (Loss) before tax (V-VI)	6.65	12.27	23.23	34.09	21.10
VII. Tax expense:					
(1) Current tax	1.52	2.60	6.70	8.49	6.58
(2) Deferred tax	2.85	2.63	7.66	10.14	7.65
	(1.33)	(0.03)	(0.96)	(1.65)	(1.07)
VIII. Net Profit/ (Loss) for the period from continuing operations (VII-VIII)	5.13	9.67	16.54	25.60	14.52
IX. Profit/(loss) from discontinued operations	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
X. Tax expenses of discontinued operations	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
XI. Profit/(loss) from Discontinued operations (after tax) (X-XI)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
XII. Profit/(loss) for the period (IX+XII)	5.13	9.67	16.54	25.60	14.52
XIII. Other Comprehensive Income					
A. (i) Items that will not be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
B. (i) Items that will be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
(ii) Income tax relating to items that will be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
XIV. Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	5.13	9.67	16.54	25.60	14.52
XV. Earnings per equity share (for continuing operation):					
(1) Basic	0.06	0.12	0.20	0.32	0.18
(2) Diluted	0.06	0.12	0.20	0.32	0.18
XVI. Earnings per equity share (for discontinuing operation):					
(1) Basic	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
(2) Diluted	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
XVII. Earnings per equity share (for discontinuing & continuing operation):					
(1) Basic	0.06	0.12	0.20	0.35	0.18
(2) Diluted	0.06	0.12	0.20	0.35	0.18

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956



TRIMURTHI LIMITED
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)



SCHEDULE III OF THE COMPANIES ACT 2013

TRIMURTHI
GROUP

PART-II

Particulars	Quarter Ended		Nine Months Ended		
	31-12-2017	30-09-2017	31-12-2016	31-12-2017	31-12-2016
	UnAudited	UnAudited	UnAudited	Unaudited	Unaudited
A. Particulars Of Share Holding					
1. Public Share Holding					
- Number of Shares	2900600	2900600	2849600	2900600	2849600
- Percentage of shareholding	35.81%	35.81%	35.18%	35.81%	35.18%
2. Promoters and promoter group shareholding					
a. Pledged / encumbered					
- No of Equity Shares	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
- Percentage of Shares (of the shareholding of promoter and promoter group)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
- Percentage of Shares (of the total share capital of the company)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
b. Non encumbered					
- No of Equity Shares	5199400	5199400	5250400	5199400	5250400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.19%	64.19%	64.82%	64.19%	64.82%

Particulars	3 Months Ended (31/12/2017)
B. Investor Complaints	
Pending at the beginning of the quarter	-NIL-
Received during the quarter	-NIL-
Disposed during the quarter	-NIL-
Remaining unsolved during the quarter	-NIL-

Segment Reporting

Particulars	Quarters ended			Nine Months Ended	
	31-12-2017	30-09-2017	31-12-2016	31-12-2017	31-12-2016
	Audited	Unaudited	Audited	Unaudited	Unaudited
1. Segment Revenue					
a. Pharma Business	0.00	0.00	0.00	0.00	0.00
b. Financial Services	19.91	21.64	23.19	63.06	47.40
c. Investments	0.00	0.00	9.47	0.00	9.47
d. Trading in Shares	84.70	5.51	81.11	121.83	278.67
Total	104.60	27.16	113.77	184.89	335.54
Less: Inter Segment Revenue	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
Net Sales/ Income From Operations	104.60	27.16	113.77	184.89	335.54
2. Segment Profits (Before tax & Interest From Each Segment)					
a. Pharma Business	0.00	0.00	0.00	0.00	0.00
b. Financial Services	14.15	14.62	13.21	44.40	22.19
c. Investments	0.00	0.00	7.24	0.00	9.47
d. Trading in Shares	(7.37)	(2.49)	2.78	(10.31)	(10.41)
Total	5.05	12.13	23.23	34.09	21.25
Less:					
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
Total Profit Before Tax	5.05	12.13	23.23	34.09	21.25
3. Capital Employed					
a. Pharma Business	0.00	0.00	0.00	0.00	0.00
b. Financial Services	(43.44)	(33.82)	181.55	601.72	653.06
c. Investments	0.00	0.00	(180.35)	184.34	179.34
d. Trading in Shares	47.38	46.24	21.86	399.36	326.14
Total	8.10	12.42	23.06	1185.41	1158.54

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956





TRIMURTHI GROUP

Notes:

- 1 The format for the Unaudited quarterly results as prescribed in SEBI Cicular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirments of SEBI Circular CRI/CFD/FAC/62/2016 dated July 5, 2016 and exemption as given under clause 2.6.1(iii) has been availed. Hence, figures of corresponding previous quarter and previous year have not been provided.
- 2 There is a possibility that these quarterly financial results may require adjustment before compiling the final Ind AS financial statements as of and for the year ending March 31, 2018 due to changes in financial reporting requirements arising from new or revised standards or interpretations issued by MCA or changes in the use of one or more optional exemptions from retorspective application of certain Ind AS as permitted under Ind AS 101
- 3 Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- 4 The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Saturday, 10th february, 2018
- 5 The Standalone Unaudited Financial Results have been prepared and subjected to Limited Review by the Statutory Auditors in accordance with Indian Accounting Standards (Ind-AS) as notified by Ministry of Corporate Affairs; Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III Division II of Companies Act, 2013. The Limited Review was carried out by Statutory Auditors for the Quarter ended 31st December, 2017. The Ind AS Complaint figures for the Corresponding previous Quarter ended 31st December, 2016 have not been subject to review or audit, however the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- 6 The results are also available on the webiste of the Company
- 7 Reconciliation between Financial Results previously reported (referred to as PREVIOUS GAAP) and Ind AS for the Quarter ended 31st Decemberr, 2017 (As per paragraph 32 of Ind AS 101)

Particulars	Quarter Ended 31/12/2017 (Rs. In Lacs)	Nine Months Ended	
		31/12/2016	(Rs. In Lacs)
Net Profit as per previous GAAP	5.13	14.52	
Increase in profit due to:	NIL	NIL	
Fair Value Impact for financial instrument	NIL	NIL	
Net Profit after Ind AS (After Tax)	5.13	14.52	
Other Comprehensive Income	NIL	NIL	
Total Comprehensive Income under Ind AS	NIL	NIL	

Place : Hyderabad
Date : 10-02-2018



TRIMURTHI LIMITED
 (Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
 4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
 Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
 Email : info@trimurthidrugs.com
 Website : www.trimurthidrugs.com
 CIN No : L67120TG1994PLC018956






P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

To
The Board of Directors
Trimurthi Limited
Hyderabad

Limited Review Report for the quarter and nine months ended 31st December, 2017

1. We have reviewed the accompanying statement of unaudited financial results of **M/s. Trimurthi Limited** (The Company) for the quarter and nine months ended 31st December, 2017, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors in their meeting held on 10th February 2018. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of interim financial information performed by the independent auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and





P. MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Ind AS and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure requirements) Regulations, 2015 and SEBI circular dated 05th July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.

Chartered Accountants

FRN: 007257S

A Krishna Rao

Partner

M.No. 020085



Place: Hyderabad

Date: 10-02- 2018